Profile data is unavailable for this security.
About the company
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
- Revenue in USD (TTM)3.72m
- Net income in USD-67.04m
- Incorporated1989
- Employees66.00
- LocationArmata Pharmaceuticals Inc5005 Mcconnell AveLOS ANGELES 90066United StatesUSA
- Phone+1 (310) 665-2928
- Fax+1 (310) 665-2963
- Websitehttps://www.armatapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aileron Therapeutics Inc | 0.00 | -25.22m | 80.81m | 15.00 | -- | 1.44 | -- | -- | -3.25 | -3.25 | 0.00 | 4.67 | 0.00 | -- | -- | 0.00 | -40.88 | -65.99 | -43.02 | -75.37 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.43 | -- | -- | -- |
| Ovid Therapeutics Inc | 567.53k | -29.75m | 81.62m | 40.00 | -- | 0.918 | -- | 143.81 | -0.4218 | -0.4218 | 0.008 | 1.25 | 0.0045 | -- | -- | 14,188.25 | -23.39 | -20.78 | -25.86 | -23.27 | -- | -- | -5,241.56 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -4.71m | 81.79m | 12.00 | -- | 8.05 | -- | -- | -0.362 | -0.362 | 0.00 | 0.781 | 0.00 | -- | -- | 0.00 | -37.91 | -- | -37.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Aclaris Therapeutics Inc | 32.02m | -58.68m | 82.05m | 91.00 | -- | 0.613 | -- | 2.56 | -0.8267 | -0.8267 | 0.4509 | 1.88 | 0.1614 | -- | 84.70 | 351,824.20 | -29.58 | -47.29 | -32.76 | -53.87 | 42.63 | 44.00 | -183.28 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -48.41m | 82.57m | 47.00 | -- | 2.58 | -- | -- | -1.01 | -1.01 | 0.00 | 0.6003 | 0.00 | -- | -- | 0.00 | -51.98 | -48.44 | -55.36 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.6171 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Bioatla Inc | 0.00 | -104.56m | 83.14m | 65.00 | -- | 2.65 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
| Vistagen Therapeutics Inc | 970.40k | -33.19m | 85.22m | 41.00 | -- | 0.8132 | -- | 87.82 | -1.53 | -1.53 | 0.0386 | 3.87 | 0.0151 | -- | -- | 24,882.05 | -51.63 | -62.84 | -56.12 | -68.03 | -- | -- | -3,420.44 | -5,768.52 | -- | -- | 0.00 | -- | 568.10 | -- | 50.44 | -- | -18.91 | -- |
| Beyondspring Inc | 1.88m | -15.57m | 85.84m | 35.00 | -- | -- | -- | 45.76 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
| Armata Pharmaceuticals Inc | 3.72m | -67.04m | 86.84m | 66.00 | -- | -- | -- | 23.35 | -1.95 | -1.95 | 0.0893 | -1.28 | 0.0355 | -- | 0.7532 | 56,348.48 | -64.00 | -59.78 | -385.50 | -72.70 | -- | -- | -1,802.72 | -1,113.72 | -- | -1.99 | 1.71 | -- | -17.77 | -- | -87.03 | -- | 184.10 | -- |
| Allovir Inc | 0.00 | -140.34m | 88.31m | 112.00 | -- | 0.7338 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| Hillevax Inc | 0.00 | -156.27m | 89.61m | 90.00 | -- | 0.4329 | -- | -- | -3.38 | -3.38 | 0.00 | 4.16 | 0.00 | -- | -- | 0.00 | -55.47 | -- | -63.02 | -- | -- | -- | -- | -- | -- | -- | 0.1113 | -- | -- | -- | 22.68 | -- | -- | -- |
| bluebird bio Inc | 45.69m | -302.96m | 91.18m | 375.00 | -- | 0.6946 | -- | 2.00 | -2.44 | -2.44 | 0.3452 | 0.677 | 0.069 | 3.28 | -- | 121,837.30 | -45.76 | -34.75 | -66.24 | -40.84 | -22.60 | -124.35 | -663.09 | -5,770.41 | 0.8219 | -28.60 | 0.615 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 91.79m | 228.00 | -- | 0.3407 | -- | 1.64 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 145.67m | -89.91m | 92.02m | 325.00 | -- | -- | -- | 0.6317 | -0.8356 | -0.8356 | 1.17 | -1.06 | 0.5692 | 1.62 | 4.15 | 448,209.20 | -35.14 | -53.02 | -45.50 | -65.85 | 96.04 | 97.18 | -61.72 | -125.15 | 3.56 | -7.37 | 2.00 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
Data as of Sep 21 2024. Currency figures normalised to Armata Pharmaceuticals Inc's reporting currency: US Dollar USD
3.71%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Bank of America, NA (Private Banking)as of 30 Jun 2024 | 634.03k | 1.75% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 201.79k | 0.56% |
| Geode Capital Management LLCas of 30 Jun 2024 | 106.49k | 0.29% |
| Edgewood Management LLCas of 30 Jun 2024 | 100.00k | 0.28% |
| Bridgeway Capital Management LLCas of 30 Jun 2024 | 90.38k | 0.25% |
| Susquehanna Financial Group LLLPas of 30 Jun 2024 | 64.01k | 0.18% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 48.20k | 0.13% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 40.30k | 0.11% |
| SeaCrest Wealth Management LLCas of 30 Jun 2024 | 34.95k | 0.10% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 20.62k | 0.06% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
